<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823741</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0997</org_study_id>
    <secondary_id>2021-A00748-33</secondary_id>
    <nct_id>NCT04823741</nct_id>
  </id_info>
  <brief_title>Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma</brief_title>
  <acronym>SCITH-MESO</acronym>
  <official_title>Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or&#xD;
      secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an&#xD;
      exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is&#xD;
      to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the&#xD;
      SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of&#xD;
      MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will&#xD;
      increase a tissue bank collection (CRB).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).</measure>
    <time_frame>day 1 (day of chirurgie)</time_frame>
    <description>For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mesothelioma, Malignant</condition>
  <condition>Gene Abnormality</condition>
  <condition>Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA</arm_group_label>
    <description>All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA</intervention_name>
    <description>All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).</description>
    <arm_group_label>PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      pleural samples of malignant pleural mesothelioma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        all patient with suspected malignant pleural mesothelioma requiring surgical biopsy for&#xD;
        diagnosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;18&#xD;
&#xD;
          -  suspected MPM requiring VATS biopsy after multidisciplinary oncologic board validation&#xD;
&#xD;
          -  patient able to understand study objectives and able to give an informed consent&#xD;
&#xD;
          -  patient affiliated to an healthcare society.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  mental disease, psychiatric disorder&#xD;
&#xD;
          -  patient under protection regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Michel MAURY, MD</last_name>
    <phone>04.72.35.75.90</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-michel.maury@chu-lyon.fr</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant pleural mesothelioma</keyword>
  <keyword>intra tumoral heterogeneity</keyword>
  <keyword>genetic abnormalities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

